The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has
approved a proposal for a preferential rights issue of shares and warrants (”the Offer” or
”the Rights Issue”). Full subscription of the offer will generate about MSEK 31 before
deductions for issuing expenses.
“This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website”